Company intelligence / Profile preview

EpiCept Corporation

Tarrytown, New York, United States
Ownership
Private
Development stage
Other
01

Overview

EpiCept developed Ceplene which received marketing authorization in Europe for AML remission maintenance. The company also had several pain therapies in clinical development before merging with Immune Pharmaceuticals.

Therapeutic areas
OncologyImmunologyNeurology
Modalities
Small moleculesantibody therapeutics (post-merger)
Industry
Biotech
02

Drug pipeline

2 assets

EpiCept-NP-1

3

1 more asset in the full pipeline.

03

Partnerships

Adolor Corporation (for LidoPAIN SP in North America)Endo

Beyond the preview

Go deeper on EpiCept Corporation.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on EpiCept Corporation.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call